Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.
More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.